VUB spin-off Precirix, the clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, discloses that they signed an agreement with Eckert & Ziegler for the supply of Actinium-225.
Actinium-225 is used as an active substance in cancer treatment. The precise treatment of tumor cells, including elusive micrometastases, is enabled by this radioisotope. It emits powerful, high-energy alpha beams with short penetration depths which has a minimal impact on surrounding healthy tissue.
The ambition of Precirix is to develop new precision radiopharmaceuticals using single-domain antibodies to address the big and unmet need in the treatment of solid tumors. This will help by unlocking the value of both alpha and beta-emitting radionuclides in their broad pipeline of product candidates. Until now, clinical research and commercial use of Actinium-225 has been restricted due to the shortage of this radioisotope. This collaboration enables further research of this promising therapeutic radioisotope.